Civetta Therapeutics is developing cancer therapeutics by specifically targeting proteins with beta-propeller domains. Beta-propeller proteins control various biological complexes that are associated with cancer progression. These proteins are united by possessing a protein structural motif that can be targeted with drugs in a specific manner. Civetta is exploiting this biological insight to target critical protein-protein interactions of beta-propeller proteins with a high degree of selectivity. To achieve this, Civetta employs advanced computational approaches and protein interaction mapping to prioritize targets for drug discovery efforts and to discover and develop highly selective therapies against those targets.

Civetta Therapeutics

Drug notes:

About:

Jobs: